No Data
No Data
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating
BridgeBio Pharma Q1 Loss Widens, Revenue Drops
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $50 to $67
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Business Is Yet to Catch Up With Its Share Price
S&P 500 Futures Fall In Premarket Trading; Super Micro Computer, ICL Group Lag
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and BridgeBio Pharma (BBIO)